Feedback / Questions
istiratumab (MM-141) - Ipsen
Merrimack Pharma: Cantor Fitzgerald Healthcare Conference
(Merrimack)
-
Jul 11, 2015 -
"MM-141 IGF-1+ Patients Stayed on Therapy 80% Longer than IGF-1-Patients (n=27)"; "Phase 1 Data Presented at AACR 2015"
P1 data
•
Oncology
http://files.shareholder.com/downloads/AMDA-IWDM2/424444453x0x838153/E068BFA4-4B6B-4CFE-A409-79E8447888E5/Merrimack_Cantor_Fitzgerald_8July_Presentation.pdf
Jul 11, 2015
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious